论文部分内容阅读
公司是两市为数不多的品牌植物药上市公司,主导产品前列康在同类产品中的市场占有率达到90%,是国内中药前列腺治疗领域第一品牌。由于该股在I66的相对排名有所下降,所以,被剔除出I66。从最近一段时期分析师对该股的盈利预测来看,大都以维持为主。
The company is one of the few listed companies in the two cities of the brand of plant medicine, the leading product front row in similar products in the market share of 90%, is the first Chinese medicine in the field of prostate treatment brand. The stock was removed from I66 due to its relative decline in I66. Analysts from the most recent period of the stock’s earnings forecast, mostly to maintain the main.